Analyst desks were busy on Monday, with notable moves across financials, technology, and healthcare.
The biggest banking call was a downgrade of TFC. Truist Financial was cut from Hold to Sell, with the consensus target sitting at $55.32. The stock carries a market cap of $63.5 billion. The move comes as regional banks face pressure from credit costs and a shifting rate outlook.
On the tech side, MRVL saw its average analyst target price lifted to $252.26 from $249.33. The $214 billion chip designer has benefited from AI infrastructure spending. CRWD also got a target bump, now averaging $181.53 versus $179.69 prior.
In healthcare, BIIB received a target price increase, with consensus moving to $222.0. Biogen's $31.9 billion market cap reflects ongoing hopes around its neuroscience pipeline. VRTX saw a recommendation removed, trimming coverage to 32 analysts.
Energy giant XOM picked up a fresh new recommendation with a consensus target of $169.48, adding to its 21-analyst coverage. SLB faced a slight target trim, with consensus slipping to $61.79.
MSFT also saw a marginal target cut to $560.21, though overall sentiment remains strongly positive with 53 buy-equivalent ratings.
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
